Synthesis and Evaluation of New Nitrofuranylamides With Collection of Mycobacterium tuberculosis Clinical Strains From Multidrug‐Resistant Tuberculosis High‐Burden Country
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Georgi M Dobrikov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Nitrofurans. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Emergence of drug‐resistant Mycobacterium tuberculosis necessitates the development of new drugs. Here, we studied the activity of new piperazine nitrofuranylamides against a collection of clinical strains from an multidrug‐resistant tuberculosis (MDR‐TB) high‐burden country. A series of nitrofuranylamides 9–15 was synthesized and evaluated using a collection of diverse clinical strains representing globally spread genotypes (Beijing, LAM, and Haarlem; susceptible, MDR, and pre‐extensively drug resistant). Minimal inhibitory concentrations (MIC) were determined using a resazurin assay. Whole‐genome sequencing was performed on an Illumina HiSeq platform. Although clinical isolates differed in their MICs, some tested compounds—namely 11 and 12 —showed higher MICs regardless of the clinical strain. In contrast, compounds 13–15 exhibited promising activity (MIC < 0.1 µg/mL) against the majority of strains. Moreover, 13 and 14 were previously shown to have low toxicity in JCL:ICR mice and low cytotoxicity against human cell lines. A closer look at structural variation indicated that the presence of a pyridine‐ or quinoline‐type aryl substituent leads to a broader spectrum of activity. The additional nitro group in 14 appears to contribute significantly to its activity. A nonsynonymous mutation in the efflux pump gene Rv3728 (372 A > V, GCC → GTC) in one of the Haarlem genotype strains may speculatively correlate with its high‐level intrinsic resistance to nitrofurans. Further biological research is warranted to investigate the mechanism of action of the most promising compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Sofia, Bulgaria.
- St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg, Russia.
- Laboratory of Molecular Epidemiology and Evolutionary Genetics, St. Petersburg Pasteur Institute, St. Petersburg, Russia.
- Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
- Henan International Joint Laboratory of Children's Infectious Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou, China.
ORCID-Profile: Georgi M Dobrikov, Violeta Valcheva, Viacheslav Zhuravlev, Igor Mokrousov
Zitieren
APA
Dobrikov, G. M., Dogonadze, M., Vyazovaya, A., Valcheva, V., Zhuravlev, V., & Mokrousov, I. (2026). Synthesis and Evaluation of New Nitrofuranylamides With Collection of Mycobacterium tuberculosis Clinical Strains From Multidrug‐Resistant Tuberculosis High‐Burden Country. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70355
Vancouver
Dobrikov GM, Dogonadze M, Vyazovaya A, Valcheva V, Zhuravlev V, Mokrousov I. Synthesis and Evaluation of New Nitrofuranylamides With Collection of Mycobacterium tuberculosis Clinical Strains From Multidrug‐Resistant Tuberculosis High‐Burden Country. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70355
BibTeX
@article{Dobrikov2026,
author = {Dobrikov, Georgi M and Dogonadze, Marine and Vyazovaya, Anna and Valcheva, Violeta and Zhuravlev, Viacheslav and Mokrousov, Igor},
title = {Synthesis and Evaluation of New Nitrofuranylamides With Collection of Mycobacterium tuberculosis Clinical Strains From Multidrug‐Resistant Tuberculosis High‐Burden Country},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70355}
}
EUVIMED